FORCE improves the lives of the millions of individuals and families facing hereditary breast, ovarian, pancreatic, prostate, colorectal and endometrial cancers. Our community includes people with a BRCA, ATM, PALB2, CHEK2, PTEN or other inherited gene mutation and those diagnosed with Lynch syndrome. We accomplish this through our education, support, advocacy and research efforts.
We are dedicated to providing up-to-date, expert-reviewed information and resources that help people make informed medical decisions. Our strong, supportive community of peers and professionals ensures no one must face hereditary cancer alone. FORCE serves as a champion, unifying the community and advocating for awareness, access to care, and better treatment and prevention options.
Updated Genetic Test Results Were Key for Chris Evert's Ovarian Cancer Diagnosis
March 19th 2022Tennis star Chris Evert shared her story about how updated information regarding her sister's genetic test results led to her own genetic testing and decision to remove her ovaries to lower her cancer risk.
Read More
Expanded Genetic Testing Uncovered an ATM Mutation
January 31st 2022This knowledge of genetic testing allowed one woman to make further decisions about her health care as well as share the news with other family members were able to have testing and make the decisions that were right for them.
Read More
The Drug Olaparib Reduces Recurrence Among Those With Early-Stage, High-Risk Breast Cancer
October 13th 2021People with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence may benefit from treatment with Lynparza (olaparib).
Read More